These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17224778)

  • 1. Trends in treatment costs for localized prostate cancer: the healthy screenee effect.
    Zeliadt SB; Etzioni R; Ramsey SD; Penson DF; Potosky AL
    Med Care; 2007 Feb; 45(2):154-9. PubMed ID: 17224778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
    Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.
    Sadetsky N; Lubeck DP; Pasta DJ; Latini DM; DuChane J; Carroll PR
    BJU Int; 2008 Mar; 101(6):691-7. PubMed ID: 18291018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
    Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
    Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
    Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
    J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of care for elderly cancer patients in the United States.
    Yabroff KR; Lamont EB; Mariotto A; Warren JL; Topor M; Meekins A; Brown ML
    J Natl Cancer Inst; 2008 May; 100(9):630-41. PubMed ID: 18445825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
    Sommers BD; Beard CJ; D'Amico AV; Dahl D; Kaplan I; Richie JP; Zeckhauser RJ
    Cancer; 2007 Nov; 110(10):2210-7. PubMed ID: 17893907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management.
    Nguyen PL; Chen MH; Catalona WJ; Alexander BM; Roehl KA; Loeb S; D'Amico AV
    Cancer; 2008 Dec; 113(11):3146-52. PubMed ID: 18932254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes.
    Barry MJ; Fleming C; Coley CM; Wasson JH; Fahs MC; Oesterling JE
    Urology; 1995 Sep; 46(3):277-89. PubMed ID: 7544931
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
    Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J
    J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
    Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
    Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Screening of cancer of the prostate (IV). Economic approach: the costs of screening tests and treatment. Members of the Sub-Committee of the Prostate of CCAFU].
    Haillot O; Villers A; Soulie M; Baron JC
    Prog Urol; 1998 Sep; 8(4):517-23. PubMed ID: 9834514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer.
    Corcoran AT; Peele PB; Benoit RM
    Urology; 2010 Sep; 76(3):703-7. PubMed ID: 20381846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.